In the wake of the increase in Current Liabilities in the first quarter 2024, Quick Ratio fell to 0.16 a new company low.

Within Major Pharmaceutical Preparations industry 456 other companies have achieved higher Quick Ratio than Vbi Vaccines Inc in first quarter 2024. While Quick Ratio total ranking in the first quarter 2024 has deteriorated compared to the prior quarter from 2424 to 3570.

Explain Quick Ratio?
How much Cash & cash equivalents VBIV�s has?
What are VBIV�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VBIV Quick Ratio	(Mar 31 2024) Q1	(Dec 31 2023) Q4	(Sep 30 2023) Q3	(Jun 30 2023) Q2	(Mar 31 2023) Q1
Y / Y Current Liabilities Change	142.19 %	92.6 %	95.67 %	-32.14 %	-12.15 %
Y / Y Cash & cash equivalent Change	-68.82 %	-62.18 %	-57.57 %	-74.71 %	-60.14 %
Quick Ratio MRQ	0.16	0.31	0.45	0.69	1.23
VBIV's Total Ranking	# 3570	# 2424	# 2303	# 1968	# 1068
Seq. Current Liabilities Change	2.58 %	-1.72 %	162.56 %	-8.51 %	-18.42 %
Seq. Cash & cash equivalent Change	-46.82 %	-33.2 %	70.12 %	-48.41 %	-35.51 %

Quick Ratio first quarter 2024 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 457
Healthcare Sector	# 907
Overall Market	# 3570

Quick Ratio Statistics
High	Average	Low
19.78	4.88	0.16
(Dec 31 2012)		(Mar 31 2024)

Financial Statements
Vbi Vaccines Inc's Current Liabilities	$ 79 Millions	Visit VBIV's Balance sheet
Vbi Vaccines Inc's Cash & cash equivalent	$ 13 Millions	Visit VBIV's Balance sheet
Source of VBIV's Sales		Visit VBIV's Sales by Geography

Cumulative Vbi Vaccines Inc's Quick Ratio

VBIV's Quick Ratio for the trailling 12 Months

VBIV Quick Ratio	(Mar 31 2024) 12 Months	(Dec 31 2023) 12 Months	(Sep 30 2023) 12 Months	(Jun 30 2023) 12 Months	(Mar 31 2023) 12 Months
Y / Y Current Liabilities TTM Growth	68.69 %	35.18 %	14.38 %	-7.7 %	12.85 %
Y / Y Cash & cash equivalent TTM Growth	-65.58 %	-63.52 %	-59.04 %	-53.17 %	-45.72 %
Quick Ratio TTM	0.35	0.55	0.88	1.45	1.71
Total Ranking TTM	# 3676	# 3711	# 2095	# 3597	# 3281
Seq. Current Liabilities TTM Growth	21.29 %	20.48 %	26.89 %	-9.03 %	-2.8 %
Seq. Cash & cash equivalent TTM Growth	-23.09 %	-24.44 %	-23.19 %	-22.89 %	-18.47 %

Quick ratio ranking by company, industry and sector >> Back to VBIV Financial Strength Comparisons >> Go to Compare VBIV Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q1 2024 to $79.41 millions, cumulative Quick Ratio decreased to 0.35 below the Vbi Vaccines Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 478 other companies have achieved higher Quick Ratio than Vbi Vaccines Inc. While Quick Ratio overall ranking has improved so far to 3676, from total ranking during the twelve months ending fourth quarter 2023 at 3711.

Explain Quick Ratio?
How much Cash & cash equivalents VBIV�s has?
What are VBIV�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 479
Healthcare Sector	# 995
Within the Market	# 3676

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.58	3.35	0.36
(March 31, 2015)		(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2024 MRQ Cash & cash equivalent	Mar 31 2024 MRQ Current Liabilities
Abbvie Inc	0.44	$ 18,069.000 Millions	$ 41,522.000 Millions
Longeveron Inc	0.43	$ 2.291 Millions	$ 5.295 Millions
Supernus Pharmaceuticals inc	0.43	$ 63.401 Millions	$ 147.328 Millions
Virpax Pharmaceuticals Inc	0.43	$ 1.866 Millions	$ 4.344 Millions
Entrada Therapeutics Inc	0.39	$ 68.436 Millions	$ 173.938 Millions
Prestige Consumer Healthcare Inc	0.39	$ 46.469 Millions	$ 120.373 Millions
Elanco Animal Health Incorporated	0.38	$ 345.000 Millions	$ 914.000 Millions
Bristol myers Squibb Company	0.37	$ 9,670.000 Millions	$ 25,822.000 Millions
Opko Health Inc	0.37	$ 75.639 Millions	$ 204.338 Millions
Casi Pharmaceuticals inc	0.37	$ 13.468 Millions	$ 36.452 Millions
Ac Immune Sa	0.36	$ 40.003 Millions	$ 111.202 Millions
Intercure Ltd	0.35	$ 21.439 Millions	$ 62.070 Millions
Tonix Pharmaceuticals Holding Corp	0.34	$ 7.049 Millions	$ 20.479 Millions
Bio Green Med Solution Inc	0.34	$ 2.798 Millions	$ 8.350 Millions
Novartis Ag	0.33	$ 9,602.000 Millions	$ 28,692.000 Millions
Pfizer Inc	0.31	$ 11,928.000 Millions	$ 37,995.000 Millions
Lakeshore Biopharma Co Ltd	0.31	$ 34.722 Millions	$ 113.069 Millions
Hcw Biologics Inc	0.30	$ 4.084 Millions	$ 13.413 Millions
Integrated Biopharma Inc	0.29	$ 2.020 Millions	$ 6.945 Millions
Eli Lilly And Company	0.28	$ 2,586.300 Millions	$ 9,168.500 Millions
Sanofi	0.28	$ 9,144.800 Millions	$ 32,661.440 Millions
International Stem Cell Corporation	0.28	$ 1.386 Millions	$ 4.966 Millions
Biofrontera Inc	0.27	$ 3.817 Millions	$ 14.036 Millions
Ibio inc	0.25	$ 5.352 Millions	$ 21.426 Millions
The Greater Cannabis Company Inc	0.25	$ 0.129 Millions	$ 0.518 Millions
Cdt Equity Inc	0.24	$ 1.844 Millions	$ 7.722 Millions
Akari Therapeutics Plc	0.24	$ 1.310 Millions	$ 5.509 Millions
Aytu Biopharma Inc	0.24	$ 19.760 Millions	$ 83.689 Millions
Geovax Labs Inc	0.23	$ 0.769 Millions	$ 3.304 Millions
Organon and Co	0.23	$ 575.000 Millions	$ 2,545.000 Millions

Date modified: 2026-09-26T07:31:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.